Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2022

Open Access 01-12-2022 | Metastasis | Correction

Correction to: Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals

Authors: Wei Zhai, Saiyang Li, Jin Zhang, Yonghui Chen, Junjie Ma, Wen Kong, Dongkui Gong, Junhua Zheng, Wei Xue, Yunfei Xu

Published in: Molecular Cancer | Issue 1/2022

Login to get access

Excerpt

Correction to: Mol Cancer 17, 157 (2018) …
Literature
1.
Metadata
Title
Correction to: Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals
Authors
Wei Zhai
Saiyang Li
Jin Zhang
Yonghui Chen
Junjie Ma
Wen Kong
Dongkui Gong
Junhua Zheng
Wei Xue
Yunfei Xu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2022
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-022-01568-y

Other articles of this Issue 1/2022

Molecular Cancer 1/2022 Go to the issue

Letter to the Editor

DNA methylation-associated dysregulation of transfer RNA expression in human cancer

Letter to the Editor

Clustering cancers by shared transcriptional risk reveals novel targets for cancer therapy

Correction

Correction to: Circular RNA circERBB2 promotes gallbladder cancer progression by regulating PA2G4-dependent rDNA transcription

Review

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Correction

Correction: A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1

Research

Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits